Codiak Biosciences Inc logo

CDAK

Codiak Biosciences Inc

$2.48

Earnings Summary

Revenue
$13.15Mn
Net Profits
$-6.78Mn
Net Profit Margins
-51.54%

Highlights

Revenue:

Codiak Biosciences Inc’s revenue jumped 1376.97% since last year same period to $13.15Mn in the Q2 2022. On a quarterly growth basis, Codiak Biosciences Inc has generated 3.47% jump in its revenue since last 3-months.

Net Profits:

Codiak Biosciences Inc’s net profit jumped 68.93% since last year same period to $-6.78Mn in the Q2 2022. On a quarterly growth basis, Codiak Biosciences Inc has generated 15.61% jump in its net profits since last 3-months.

Net Profit Margins:

Codiak Biosciences Inc’s net profit margin jumped 97.9% since last year same period to -51.54% in the Q2 2022. On a quarterly growth basis, Codiak Biosciences Inc has generated 18.44% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Codiak Biosciences Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.84
EPS Estimate Current Year
-0.84

Highlights

EPS Estimate Current Quarter:

Codiak Biosciences Inc’s earning per share (EPS) estimates for the current quarter stand at -0.84 - a 5.62% jump from last quarter’s estimates.

EPS Estimate Current Year:

Codiak Biosciences Inc’s earning per share (EPS) estimates for the current year stand at -0.84.

Key Ratios

Key ratios of the Codiak Biosciences Inc post its Q2 2022 earnings

Return on Assets (ROA)
-0.22
Return on Equity (ROE)
-0.41
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Codiak Biosciences Inc’s return on assets (ROA) stands at -0.22.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Codiak Biosciences Inc’s return on equity (ROE) stands at -0.41.

Dividend Per Share (DPS):

Codiak Biosciences Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.89
-0.36
59.55%

Company Information

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of diseases, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Organisation
Codiak Biosciences Inc
Headquarters
Cambridge, Massachusetts, United States
Employees
105
Industry
Commercial Services
CEO
Douglas Williams